

Paris and Toulouse, August 8, 2016

Limited company (société anonyme) with a Management Board (directoire)  
and a Supervisory Board (conseil de surveillance)  
with share capital of €1,557,005.50  
Registered Office: Prologue-Biotech, 516 Rue Pierre et Marie Curie, 31670 Labège, France  
Toulouse Trade and Companies Register (RCS) B 439 489 022

## **HALF-YEAR SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE**

Pursuant to the liquidity contract granted to Oddo Corporate Finance regarding Genticel shares, the following resources were listed in the liquidity account as of June 30, 2016, settlement date:

- 45,353 Genticel shares;
- 43,699.95 euros.

As of December 31st, 2015, the most recent update, the following resources had been allocated to the liquidity account:

- 15,051 Genticel shares;
- 116,748.22 euros.

### **About Genticel**

#### ***Aiming to solve a public health issue.***

*Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and 275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early stage with GTL001, its first-in-class immunotherapeutic candidate. GTL001 clinical efficacy is being evaluated in a 24-month proof of concept Phase 2 trial in Europe.*

#### ***Offering a promising technological platform.***

*Genticel's versatile platform, Vaxiclase, is well suited for the development of immunotherapies against multiple infectious or cancerous diseases. A partnership on the use of Vaxiclase has already been established with Serum Institute of India Ltd (SILL), the largest producer of vaccine dose worldwide. This agreement covers territories outside of the USA and Europe, and could generate up to \$57 million in revenues for Genticel, before royalties on sales. It will enable SILL to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough.*

**For more information, visit [www.genticel.com](http://www.genticel.com)**



### **Forward Looking Statement**

*This press release contains forward-looking statements that are not promises or guarantees and involve substantial risks and uncertainties. The Company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory*

reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French "Autorité des Marchés Financiers", including in the Company's Annual Report for the year ended December 31, 2015 and future filings and reports by the Company which are available on the Company's website.. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GenticeI undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.

#### **GENTICEI**

Valerie Leroy  
Investor Relations & Corporate  
Communications  
+ 33 6 33 34 37 30  
[investors@genticeI.com](mailto:investors@genticeI.com)

#### **US INVESTORS**

**Life Sci Advisors**  
Brian Ritchie  
+1 212 915 2578  
[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)

#### **MEDIA**

**ALIZE RP**  
Caroline Carmagnol et  
Florence Portejoie  
+33 6 64 18 99 59 / +33 6 47 38 90 04  
[genticeI@alizerp.fr](mailto:genticeI@alizerp.fr)